Champions Oncology, Inc.
CSBR
$5.96
$0.111.88%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.56M | 15.04M | 14.00M | 12.36M | 17.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.56M | 15.04M | 14.00M | 12.36M | 17.04M |
| Cost of Revenue | 8.83M | 7.26M | 8.00M | 7.27M | 6.62M |
| Gross Profit | 7.73M | 7.77M | 6.00M | 5.08M | 10.42M |
| SG&A Expenses | 5.64M | 4.97M | 4.43M | 4.84M | 4.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.75M | 14.85M | 14.50M | 14.07M | 12.54M |
| Operating Income | -187.00K | 185.00K | -507.00K | -1.71M | 4.50M |
| Income Before Tax | -237.00K | 255.00K | -452.00K | -1.96M | 4.52M |
| Income Tax Expenses | 42.00K | 18.00K | 14.00K | -129.00K | 23.00K |
| Earnings from Continuing Operations | -279.00K | 237.00K | -466.00K | -1.84M | 4.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 31.00K | 30.00K | -- | -- |
| Net Income | -279.00K | 268.00K | -436.00K | -1.84M | 4.50M |
| EBIT | -187.00K | 185.00K | -507.00K | -1.71M | 4.50M |
| EBITDA | 154.00K | 542.00K | -149.00K | -1.32M | 4.90M |
| EPS Basic | -0.02 | 0.02 | -0.03 | -0.13 | 0.33 |
| Normalized Basic EPS | -0.01 | 0.01 | -0.02 | -0.08 | 0.21 |
| EPS Diluted | -0.02 | 0.02 | -0.03 | -0.13 | 0.31 |
| Normalized Diluted EPS | -0.01 | 0.01 | -0.02 | -0.08 | 0.20 |
| Average Basic Shares Outstanding | 13.89M | 13.79M | 13.79M | 13.75M | 13.70M |
| Average Diluted Shares Outstanding | 13.89M | 14.46M | 13.79M | 13.75M | 14.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |